SCHEMBL30765797

SCHEMBL30765797

C[C@H](Nc1cncn(CC(=O)OC(C)(C)C)c1=O)c1ccc2oc3ccccc3c2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.40
POLB P06746 2/20 0.36
RXFP1 Q9HBX9 2/20 0.36
MAPT P10636 5/20 0.36
LMNA P02545 4/20 0.36
RAB9A P51151 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HDAC6 Q9UBN7 2/20 0.35
USP2 O75604 1/20 0.35
HSD17B10 Q99714 1/20 0.34
F2 P00734 1/20 0.34
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
NPC1 O15118 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765867 0.88 HDAC6 (0.44) KMT2APOLBRXFP1MAPTLMNA
SCHEMBL30765801 0.86 LMNA (0.41) KMT2APOLBRXFP1MAPTLMNA
SCHEMBL30765957 0.84 ALDH1A1 (0.38) KMT2APOLBRXFP1MAPTLMNA
SCHEMBL30765995 0.83 ALDH1A1 (0.37) KMT2ARXFP1MAPTLMNAKDM4E
SCHEMBL30765991 0.83 ELANE (0.42) LMNAKDM4EALDH1A1CYP1A2CYP2C9
SCHEMBL30765931 0.83 ALDH1A1 (0.37) KMT2ARXFP1MAPTLMNAKDM4E
SCHEMBL30765941 0.83 ALDH1A1 (0.37) KMT2ARXFP1MAPTLMNAKDM4E
SCHEMBL30766046 0.82 JAK2 (0.37) KMT2ARXFP1MAPTLMNARAB9A
SCHEMBL30765521 0.81 KMT2A (0.38) KMT2APOLBRXFP1MAPTLMNA
SCHEMBL30765733 0.81 KMT2A (0.36) KMT2APOLBRXFP1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed